INTERVIEW FEED & ADDITIVE MAGAZINE March 2024 59 simpler to do business with Argenta and to provide them with peace of mind, whether that’s through research, development, or manufacturing. Importantly, there will be no changes to legal entities or who customers do business with. As a CRO/ CDMO, Argenta highly values its established relationships and working in partnership with clients. We know that you provide support to companies in the development and production of products that contribute to the health and welfare of pets and farm animals. What is the scope/content of this support? For which services and why do companies need you? Companies can come to us for comprehensive product development support from start to finish or for dedicated input where we can add most value. Argenta can now provide deep knowledge and experience across all the following areas: • Pharmaceutical sciences: Designing and optimising the composition, stability, and delivery mechanisms of drugs to ensure efficacy, safety, and compliance. • Novel Drug Delivery Technologies: Bringing innovative thinking to drug development programs using licensable novel delivery technologies. • Pre-clinical services (including in the USA through Midwest Veterinary Services (MVS)): Assessing the safety, efficacy, and pharmacokinetics of a veterinary medicinal product, animal feed, or device before it is tested in a veterinary clinical trial. • Clinical research: Delivering superior science and the highest quality data through well-managed clinical studies and innovative solutions. • Regulatory affairs: Maximising the product development process and reducing time to market with expertise in navigating the complexity of regulatory requirements on a global level (e.g., EMA, FDA, and EFSA). • Manufacturing: Commercialising at scale in three EMA/FDA-approved GMP-compliant manufacturing facilities. • Consultancy: Strategically advising companies wherever they are in their development process to help them overcome their toughest challenges. What can you tell us about your future plans and goals regarding the animal nutrition and health sectors? We will continue to build on--and improve--our current capabilities and listen to our customers’ and market needs to identify areas where we can expand our services. Our new energised Argenta brand and the “One Brand, One Vision” campaign emphasises Argenta's long-term commitment to advancing world-class treatments, therapies and nutrition for healthier and happier animals by delivering trusted, innovative ‘molecule to market’ solutions. About Will Downie An accomplished and purpose-driven leader, Will Downie is Argenta’s Chief Executive Officer (CEO). With a passion for building high-performing teams and creating collaborative cultures, Will has a strong track record in helping companies to successfully transform their businesses in both publicly listed and private equity settings. Although the CEO role at Argenta is Will’s first role in animal health, he has been the loving owner of many pets over the years and currently has a Cockapoo dog and Bengal and Siamese cats in his family. Will has a long-standing career in the healthcare industry and an extensive understanding of the drug development and manufacturing market. Prior to joining Argenta in April 2022, Will was the CEO of Vectura, a leading global CDMO for inhaled drug development solutions. In this role, he transformed the company into a global leader in its space, almost doubling the valuation. Prior to this, he was the Chief Commercial Officer at Catalent Inc. for 10 years, and earlier in his career worked in a range of senior sales and marketing positions at GE Healthcare, Sanofi and Merck. Will holds a BSc (Hons) in biochemistry from the University of Edinburgh, UK.
RkJQdWJsaXNoZXIy MTUxNjkxNQ==